The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors.
Gennaro Daniele
No relevant relationships to disclose
Malcolm Ranson
No relevant relationships to disclose
Montserrat Blanco-Codesido
No relevant relationships to disclose
Emma Jane Dean
No relevant relationships to disclose
Krunal Jitendrakumar Shah
No relevant relationships to disclose
Matthew Krebs
No relevant relationships to disclose
Andre Brunetto
No relevant relationships to disclose
Alastair Greystoke
No relevant relationships to disclose
Claire Johnston
No relevant relationships to disclose
Galina Kuznetsov
Employment or Leadership Position - Eisai
Mark Matijevic
Employment or Leadership Position - Eisai
Bipin Mistry
Employment or Leadership Position - Eisai
Begona de las Heras
Employment or Leadership Position - Eisai
L Rhoda Molife
No relevant relationships to disclose